Benzinga | Nov 22, 2021 08:05AM EST

Athenex To Present Subgroup Analysis From Phase 3 Study Of Oral Paclitaxel Plus Encequidar In Metastatic Breast Cancer At SABCS 2021

Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities



Post hoc analysis of this subgroup of patients with hepatic impairment was conducted and showed a median survival rate of 18.9 months in patients treated with Oral Paclitaxel vs 10.1 months in those treated with IV Paclitaxel, with a hazard ratio of 0.59

This increase in overall survival counterbalanced the risk of complications of neutropenia related toxicities